Neurocritical Care

, Volume 17, Issue 2, pp 177–182 | Cite as

Treatment Outcomes of Heparin-Induced Thrombocytopenia in Subarachnoid Hemorrhage Patients: A 4-Year, Retrospective Single-Center Review

  • Scott T. Benken
  • Eljim P. Tesoro
  • Keri S. Kim
  • Jeffrey J. Mucksavage
Original Article
  • 344 Downloads

Abstract

Introduction

The treatment and outcomes of heparin-induced thrombocytopenia (HIT) are not well described in neurosurgery patients. This study reviewed the treatment for HIT in subarachnoid hemorrhage (SAH) patients, and compared outcomes in patients with isolated HIT (iHIT) and HIT with thrombotic syndrome (HITTS).

Methods

Adult patients with SAH discharged from the University of Illinois Hospital & Health Sciences System from 2006 to 2009 were included if they had at least one positive HIT antibody test. Patients were categorized with either iHIT or HITTS based on documented evidence of thrombosis. The primary outcome was the incidence of new thromboses prior to discharge. Secondary outcomes included the incidence of major bleeding, new thromboses up to 3 months after discharge, or hospice/death. Patients having any secondary outcome were defined as having a “poor treatment-related effect”.

Results

A total of 176 patients were screened and 30 patients met inclusion criteria. Eighteen patients (60 %) were categorized with iHIT and 12 (40 %) with HITTS. Twelve patients (67 %) with iHIT received prophylaxis with fondaparinux and nine patients (75 %) with HITTS were treated with argatroban. There were no differences in the primary (11 vs. 25 %, p = 0.364) or secondary outcomes in the iHIT group versus the HITTS group. Patients with iHIT had a 5.5 % incidence of “poor treatment-related effects” compared to a 33.3 % incidence in patients with HITTS (p = 0.024).

Conclusions

SAH patients with iHIT and HITTS did not differ in the incidence of new thromboses, incidence of hemorrhage, or hospice/death. Patients with iHIT had fewer “poor treatment-related effects” than HITTS patients.

Keywords

Subarachnoid hemorrhage Heparin-induced thrombocytopenia Outcomes Treatment Anticoagulation Heparin Argatroban Fondaparinux 

References

  1. 1.
    Warkentin TE, Greinacher A, Koster A, Lincoff AM. American college of chest physicians treatment and prevention of heparin-induced thrombocytopenia. Chest. 2008;133:340S–80S.PubMedCrossRefGoogle Scholar
  2. 2.
    Parney IF, Steinke DE. Heparin-induced thrombocytopenia and thrombosis following subarachnoid hemorrhage. J Neurosurg. 2000;93:136–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Alaraj A, Wallace A, Mander N, Aletich V, Charbel FT, Amin-Hanjani S. Risk factors for heparin-induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage. Neurosurgery. 2011;69:1030–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Harbrecht U, Bastians B, Kredteck A, Hanfland P, Klockgether T, Pohl C. Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. Neurology. 2004;62:657–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:311S–37S.PubMedCrossRefGoogle Scholar
  6. 6.
    Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Sem Thromb Hemostat. 2006;32:803–9.CrossRefGoogle Scholar
  8. 8.
    Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106:2921–2.PubMedCrossRefGoogle Scholar
  10. 10.
    Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Eng J Med. 1995;332:1330–5.CrossRefGoogle Scholar
  11. 11.
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Eng J Med. 2001;344:1286–92.CrossRefGoogle Scholar
  12. 12.
    Kim GH, Hahn DK, Kellner CP, Komotar RJ, Starke R, Garrett MC, et al. The incidence of heparin-induced thrombocytopenia type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin. J Neurosurg. 2009;110:50–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Hoh BL, Aghi M, Pryor JC, Ogilvy CS. Heparin-induced thrombocytopenia type II in subarachnoid hemorrhage patients: incidence and complications. Neurosurgery. 2005;57:243–8. discussion 243–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56(1):12–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment of heparin-induced thrombocytopenia. Am J Med. 1999;106:629–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Wen DY, Hall WA. Complications of subcutaneous low-dose heparin therapy in neurosurgical patients. Surg Neurol. 1998;50:521–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Trepsi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, et al. Safety of perioperative subuctaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Neurosurgery. 1999;45:245–52.CrossRefGoogle Scholar
  21. 21.
    Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Eng J Med. 1998;339:80–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Scott T. Benken
    • 1
    • 2
  • Eljim P. Tesoro
    • 3
  • Keri S. Kim
    • 3
  • Jeffrey J. Mucksavage
    • 3
  1. 1.Northwestern Memorial HospitalChicagoUSA
  2. 2.Roosevelt University College of PharmacySchaumburgUSA
  3. 3.University of Illinois Hospital & Health SystemChicagoUSA

Personalised recommendations